Magenta Therapeutics completes review of its business
Magenta Therapeutics a clinical-stage biotechnology company focused on improving stem cell transplantation, announced that it has completed a review of its business, including the status of its programs, resources, and capabilities.
Magenta has made the determination to halt further development of its programs and conduct a comprehensive review of strategic alternatives focused on maximizing shareholder value.As part of this review process, Magenta will explore potential strategic alternatives that may include, but are not limited to, an acquisition, merger, business combination, or other transaction. There can be no assurance that this review process will result in Magenta pursuing a transaction or that any transaction, if pursued, will be completed on attractive terms. Magenta has not set a timetable for completion of this review process and does not intend to comment further unless or until the Board of Directors has approved a definitive course of action, the review process is concluded, or it is determined that other disclosure is appropriate.
Related news and insights
The Board of Directors of Jounce Therapeutics, Inc. a clinical-stage company focused on the discovery and development of novel cancer immunotherapies and predictive biomarkers, confirmed that Concentra Biosciences, LLC , of which Tang Capital Partners, LP is the controlling shareholder, has made an unsolicited and non-binding proposal to acquire 100% of the equity of Jounce. According to the Schedule 13D filed with the U.S. Securities and Exchange Commission (“SEC”) disclosing the Proposal, Tang Capital is currently approximately a 10.2% shareholder of Jounce.